For any holders here who have an interest in the science, worth reading this recent article on current state of play with locally adv pc, the OSL device's approved segment. This paper is from a top-notch academic group: www.ncbi.nlm.nih.gov/pmc/articles/PMC6679311/ van Veldhuisen et al 'Cancers' published July 12th 2019.
From this paper, Interesting that the OSL Panco results appear to fit bang within the range expected with current standard of care background chemotherapy, same chemo as used in PancO. This group says expect median survival 14-16 months, with resection possible in 10-35%. So a reasonable assessment would be that the PAnco results are a fair reflection of what was a safety/feasibility pilot study: solid if unspectacular. Means as I said previously we will need to see lot more evidence for this device. The other thing to note is the improved survival in those fortunate enough to be resected- median 30-35 months according to this paper. It'll be great to see the final OSL trial results and also in particular how those 10 patients resected actually fared.
OSL Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)